MeiraGTx Q3 2023 Earnings Report $5.68 -0.45 (-7.34%) As of 04:00 PM Eastern Earnings HistoryForecast MeiraGTx EPS ResultsActual EPS-$0.74Consensus EPS -$0.63Beat/MissMissed by -$0.11One Year Ago EPSN/AMeiraGTx Revenue ResultsActual Revenue$5.10 millionExpected Revenue$3.54 millionBeat/MissBeat by +$1.56 millionYoY Revenue GrowthN/AMeiraGTx Announcement DetailsQuarterQ3 2023Date11/14/2023TimeN/AConference Call ResourcesPress ReleaseMGTX Earnings HistoryPowered by Remove Ads MeiraGTx Earnings HeadlinesChardan Capital Predicts MeiraGTx FY2025 EarningsMarch 28, 2025 | americanbankingnews.comMeiraGTx Holdings: Gaining Regulatory FocusMarch 25, 2025 | seekingalpha.comForget 99% of the entire stock market. Trade this one stock insteadJeff Clark says he joined the top 1% of wealthy Americans by doing something radically simple — ignoring 99% of the stock market and trading just one specific gold stock. He calls it the “One Gold Stock Retirement” strategy. Through bull and bear markets alike, he’s used this same trade to rack up triple-digit gains — often outperforming gold itself. And he's not the only one: over 20,000 everyday investors have tapped into this approach to pursue financial freedom. Whether you’re starting with $100 or $1 million, this monthly trade could help you profit in any market — even during crashes.April 4, 2025 | InvestorPlace (Ad)MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near FutureMarch 24, 2025 | finance.yahoo.comMeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s TreatmentMarch 18, 2025 | msn.comMeiraGTx price target raised to $13 from $11 at RBC CapitalMarch 17, 2025 | markets.businessinsider.comSee More MeiraGTx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email. Email Address About MeiraGTxMeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.View MeiraGTx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
